IVIg attenuates complement and improves spinal cord injury outcomes in mice
Open Access
- 25 May 2016
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 3 (7) , 495-511
Abstract
Objective Traumatic spinal cord injury (SCI) elicits immediate neural cell death, axonal damage, and disruption of the blood–spinal cord barrier, allowing circulating immune cells and blood proteins into the spinal parenchyma. The inflammatory response to SCI involves robust complement system activation, which contributes to secondary injury and impairs neurological recovery. This study aimed to determine whether intravenous immunoglobulin (IVIg), an FDA-approved treatment for inflammatory conditions, can scavenge complement activation products and improve recovery from contusive SCI. Methods We used functional testing, noninvasive imaging, and detailed postmortem analysis to assess whether IVIg therapy is effective in a mouse model of severe contusive SCI. Results IVIg therapy at doses of 0.5–2 g/kg improved the functional and histopathological outcomes from SCI, conferring protection against lesion enlargement, demyelination, central canal dilation, and axonal degeneration. The benefits of IVIg were detectable through noninvasive diffusion tensor imaging (DTI), with IVIg treatment counteracting the progressive SCI-induced increase in radial diffusivity (RD) in white matter. Diffusion indices significantly correlated with the functional performance of individual mice and accurately predicted the degree of myelin preservation. Further experiments revealed that IVIg therapy reduced the presence of complement activation products and phagocytically active macrophages at the lesion site, providing insight as to its mechanisms of action. Interpretation Our findings highlight the potential of using IVIg as an immunomodulatory treatment for SCI, and the value of DTI to assess tissue damage and screen for the efficacy of candidate intervention strategies in preclinical models of SCI, both quantitatively and noninvasively.Keywords
Funding Information
- Wings for Life
- SpinalCure Australia
- National Health and Medical Research Council (1060538)
- Queensland Government
This publication has 52 references indexed in Scilit:
- Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1Nature Medicine, 2012
- Complement activation in the injured central nervous system: another dual-edged sword?Journal of Neuroinflammation, 2012
- Molecular mechanisms of inflammation and tissue injury after major trauma-is complement the "bad guy"?Journal of Biomedical Science, 2011
- Diffusion Tensor Imaging at 3 Hours after Traumatic Spinal Cord Injury Predicts Long-Term Locomotor RecoveryJournal of Neurotrauma, 2010
- Involvement of Fc Receptors in Disorders of the Central Nervous SystemNeuroMolecular Medicine, 2009
- B cells produce pathogenic antibodies and impair recovery after spinal cord injury in miceJournal of Clinical Investigation, 2009
- Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injuryExperimental Neurology, 2008
- Ascending central canal dilation and progressive ependymal disruption in a contusion model of rodent chronic spinal cord injuryBMC Neurology, 2007
- Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell deathProceedings of the National Academy of Sciences, 2007
- Can experiments in nonhuman primates expedite the translation of treatments for spinal cord injury in humans?Nature Medicine, 2007